

## Special Issue

# Development and Challenges of Respiratory Disease Vaccines

### Message from the Guest Editor

The respiratory system is susceptible to pathogens. Currently, vaccines are available for respiratory diseases such as influenza, COVID-19, pneumonia, pertussis, and tuberculosis (TB). Some infectious respiratory diseases do not yet have a vaccine, such as respiratory syncytial virus (RSV) and the common cold. There are still many troubling issues with existing respiratory vaccines, such as the mutants of influenza virus and SARS-CoV-2; therefore, the development of universal vaccines is now a common concern. As for the RSV vaccine, vaccine-induced pathology is a big safety hurdle. To achieve a more extensive understanding of recent scientific knowledge and current trends in the development of vaccines that protect against respiratory disease, this Special Issue is focused on the recent scientific and technical progresses made in this field. Based on your extensive knowledge and experience, we invite you to contribute research works which highlight (i) correlates of protection, (ii) the action mechanism of novel vaccine candidates, (iii) vaccine protection and vaccine pathology, and (iv) the development of novel attenuated or universal respiratory disease vaccines.

### Guest Editor

Prof. Xiaoming Yang  
National Engineering Technology Research Center for Combined Vaccines, Wuhan, China

### Deadline for manuscript submissions

closed (31 January 2024)



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/132877](https://mdpi.com/si/132877)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

---

### Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College  
Roosevelt, 4331 CB Middelburg, The Netherlands

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).